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Introduction  
Wounds are a ubiquitous part of any surgical practice and are often 
challenging to treat. They can be broadly thought of as acute or chronic and can 
have varied etiologies (1, 2).  Wounds, in one form or another, contribute to a 
significant burden on health care in terms of morbidity, cost of treatment and 
duration of healing (3,28). 
In resource-rich nations, wound management has progressed significantly 
and some countries have shown that community based wound management 
teams can help to decrease the burden on hospitals (3). However, there has been 
no real progress in reducing the time required for wound healing (4).  
Stem cells have the potential to reduce time to healing since they are able to 
differentiate into the various cell types required in wound healing (5, 6, 7, 8, 9). 
It is known that bone marrow derived stem cells have the potential to be 
recruited locally and to transform into keratinocytes and other cells promoting 
local granulation without cell-cell fusion (13, 14). It is therefore possible that 
research into this property of bone marrow derived stem cells could serve as an 
answer to the problem that has plagued surgeons for centuries: How do we 
speed up wound healing? 
 
 
Disease burden: 
It is estimated that the prevalence of wounds in the community is 15.0 per 
1000 and chronic wound prevalence is 4.48 per 1000 (29).  Diabetics in India in 
the over 20 age group are predicted to increase by 151% from the years 2000 to 
2030 (30). Diabetics have 30 to 40 times greater chances of major complications 
compared to the normal population and 15% of diabetics are estimated to have 
foot ulcers at any given time (28). It is also estimated that 40 to 77 per 10000 
diabetics have a major amputation in their life-time and that 65% of these could 
be avoided with adequate foot care (28). India will have the world’s largest 
diabetic population by 2030 (30) and this will add a further load on our already 
burdened health system. 
 
What makes an ulcer persist long enough to be considered non-healing or 
chronic and further, what can be done to improve the wound healing rates in 
such situations? 
Chronic wounds have long been held as a difficult area in any general 
surgical practice. They are difficult to treat and outcomes tend to be poor. This 
is related to the multiple factors that make a wound chronic and keep it from 
healing.  
 
The definition of a chronic wound varies in terms of duration and character 
of the wound. The most precise definition is that of a wound that has not shown 
any progress towards healing for more than or equal to one month (2, 27). 
However, this definition does not take into account the size of the wound or the 
underlying etiology of the wound.  
 
Chronic wounds or ulcers have been the source of intense debate and much 
research (1, 4). Many factors have been implicated in preventing wound healing 
and others have been identified as pro-healing. However, there has been no 
magic bullet or single agent that has been isolated that either prevents or 
promotes wound healing. This implies that wound healing is a complex and 
active process and is multi-factorial and what causes a wound to become 
chronic is still not clear (31).  
 
 
 
 
 
 
Aims & Objectives 
Objective:  
To improve current practice in the healing of chronic wounds by assessing a 
novel treatment option in a scientific manner. 
Aim : 1) To determine if the rate of wound healing in chronic wounds can be 
augmented by the local application of stem cells derived from autologous 
concentrated bone marrow aspirates. 
2) To standardize the methodology for the local application of autologous 
bone marrow derived stem cells in chronic wounds. 
Study Type: 
            Randomized controlled study in a tertiary care centre in South India, 
Christian Medical College, Vellore. 
 
 
 
 
 
Normal wound healing: 
 
Wound healing can be defined as the restoration of the normal anatomic 
integrity and function of injured tissue (27). Tissue can be injured in many 
ways, including direct trauma, incisions from surgical wounds and even 
ulceration and tissue loss due to necrosis secondary to infections of various 
types.  
 Epithelium and liver tissue are known to regenerate; this is often limited by 
scarring and fibrous tissue. While fibrosis and scarring are considered as a part 
of healing, much of normal function may be lost and in fact, the healed area 
invariably has less function and aesthetic value than previously (19). 
 
The processes involved in the healing of a wound can be simply summed up 
as (19, 27): 
• Coagulation 
• Inflammation 
• Matrix synthesis & deposition 
• Angiogenesis 
• Fibroplasia 
• Epithelialization 
• Contraction 
• Remodeling 
 
Each of these processes can be further discussed and their roles have been 
studied in detail. 
 
Coagulation: 
As soon as blood vessels are damaged in the event that caused the injury, the 
coagulation pathway is initiated. In this manner the wound healing activities 
begin almost simultaneously with the wounding event. Local activation of 
phospholipase A2 at the cell membrane causes the metabolism of arachidonic 
acid to the eicosanoid precursors and then to the prostaglandins and the 
leukotrienes. Further, the hemostatic events such as vascular constriction, 
platelet plug formation and fibrin clot deposition also occur.  As the coagulation 
cascade is activated, so are the complement cascades. These occur 
simultaneously. The platelets themselves release platelet derived growth factor, 
transforming growth factor and insulin like growth factor. These act as early 
attractants for fibroblasts and other reparative cells (19, 27). 
 
Inflammation 
Once the coagulation processes are underway, the process that is common to 
all wounds- inflammation begins. Inflammation can be identified by the 
cardinal signs of redness, heat, swelling, pain and loss of function. The cells that 
are important in this process are the polymorphonuclear cells and macrophages.  
In this process, the clots, foreign bodies and bacteria are removed and all the 
substrates required for cellular matrix deposition are arranged. The wound 
becomes erythematous and edematous as futher humoral mediators are released. 
This then continues until the wound is covered by ectodermal or endodermal 
elements such as epithelium and blood vessels (19, 27). Macrophages further 
release basic fibroblast growth factor which is a chemotactic factor for 
fibroblasts and is additionally an angiogenic stimulant (20). 
 
Matrix synthesis and deposition 
Wound healing then progresses to a point where the wound is covered with 
epithelium and fibroblasts are laid down. These are the main cells that produce 
collagen and the extracellular matrix. They also release glycosaminoglycans and 
elastin fibres. The presence of metalloproteinases in the matrix at this point is 
also a vital factor in the wound healing process. There is evidence to show that 
matrix derived metallo-proteinase 8 ( neutrophil derived) is the predominant 
collagenase present in normal wounds that are healing (33). Collagen deposition 
reaches its peak at approximately 7 days after the initial wounding and 
production escalates to a plateau at 6 weeks. The crosslinking of the collagen 
matrix also occurs during this period and defects in this stage of the wound 
healing can cause apparently healed wounds to have abnormal characteristics, 
such as greater tissue elasticity and less strength (19, 27, 35). 
 
Angiogenesis 
 
This is defined as directed endothelial cell  migration and growth and is 
stimulated by acidic and basic fibroblast growth factor that are produced by 
endothelial cells and macrophages. Any degradation of the basement 
membrane, which is a storehouse for the basic FGF causes release of this 
angiogenic factor (17). The blood vessels that are formed in response to these 
stimuli tend to thin walled, short-lived and fragile and can easily be disrupted. 
This can contribute to poor wound vascularity in an otherwise granulating 
wound (19). 
 
Epithelialization 
 
This is directly stimulated by at least two growth factors epidermal derived 
growth factor (EGF) and keratinocyte growth factor (KGF) (20).  EGF 
encourages cells to continue through the entire cell cycle and not stop 
differentiating. In the wound itself, it attracts epithelial cells, fibroblasts and 
endothelial cells. KGF, however, interacts with dermal fibroblasts and the 
extracellular matrix, contributing to epithelialization in full-thickness wounds 
by stimulating keratinocyte activity at the epidermal-dermal interface.  Wound 
healing is also marked by laminin and collagen VII which are deposited as part 
of the extracellular matrix. However, the growth factors do not appear to 
themselves be affected by levels of laminin or even collagen type VII. The 
inference from this is that they do not have a feedback system controlling their 
expression (20, 34). 
While this proceeds at the molecular level, wounds gradually remodel 
themselves till the fine layer of capillaries and vessels on the surface of the 
wound regress and only the fibroblasts remain. Wound tensile strength also 
increases with time (19, 35). 
 
Contraction 
 
The destruction of soft tissue and the eventual repair always involve more 
than one type of cell being incorporated into the wound site and formation of a 
new connective tissue matrix. As skin overgrows the defect, the normal dermal 
appendages and fibrous structure serve to cover a significant area. However, 
interspersed along the edge of the healing area is scar tissue and this contracture 
differs from wound contraction. The greatest benefit of wound contraction is 
that the area required to be covered by scar contracture is minimized. However, 
the aesthetic and functional loss associated with wound contraction and scar 
contracture may be significant as can be seen in joint creases in burn wounds. 
As the fibroblast migration through the extracellular matrix occurs, the collagen 
fibrils are oriented into a streamlined shape. In conjunction with collagenase 
activity, there is normal orientation of collagen and extracellular matrix 
strengthening (19, 31, 35). 
 The myofibroblast is a connective tissue cell of mesenchymal origin with 
alpha-smooth muscle actin as its hallmark. Overwhelming evidence points to 
the myofibroblast being the cell that is mainly responsible for wound 
contractions.  Its presence helps in the re-orientation of the connective tissue 
around the wound edges. The dynamic force through the actin-myosin coupling 
effects is responsible for the wound and subsequent scar contracture (19). While 
being derivatives of the fibroblasts,  myofibroblasts are also found to have a 
fibronexus which is a special entity that connects their cytoskeleton to the 
extracellular connective tissue matrix.  This links the cell membrane between 
intracellular microfilaments and extracellular fibronectin. 
 Due to the presence of these specialised cells, the granulation tissue 
responds to drugs that stimulate smooth muscles and this could be a source for 
further discoveries into ways to promote rapid scar contraction. The presence of 
myofibroblasts at the wound site correlates with scar contracture. As the 
fibroblast activity decreases, myofibroblasts appear and promote scar formation. 
If there is a delay in apoptosis of the myofibroblasts, then their activity is 
prolonged, resulting in an abnormal balance extracelluar matrix, which results 
in a rigid, excessive scar (27, 34, 35).  This, along with the presence of 
uncontrolled matrix deposition leads to hypertrophic scarring. 
 
 
 
Remodeling 
 
This is itself a vast topic and is the concern for a large volume of current 
research. At the heart of this is the collagen molecule, which is a triple helix. 
There are nine different types of collagen and abnormalities in their production 
can cause inherited diseases such as Ehler-Danlos syndrome and Marfan’s 
syndrome. These syndromes are characterized by abnormalities in tissue tensile 
strength and healing.  
Normal extracellular matrix consists of 80% type I collagen and 20 % type II 
collagen. In the initial part of remodeling, the levels of type III collagen rise for 
3 to 4 days and then are followed by an increase in the levels of type I collagen. 
This is consistent with the early appearance and subsequent replacement of 
granulation tissue (rich in type III collagen) by collagen dominated ECM (rich 
in type I). Accumulation of collagen depends on the ratio of degradation versus 
synthesis and any healing wound will have lower degenerative enzyme levels 
compared to the synthetic enzymes. 
 
This stage is extremely pertinent to wounds that convert from healing to non-
healing ones. Any interruption in the synthesis of collagen or of its remodeling 
will disrupt wound healing. Some factors that have been implicated in this are 
deficiency of ascorbic acid which is required in the production of prolyl 
hydroxylase (19, 20), a rate limiting enzyme in the manufacture of collagen.  
Hypoxia has also been implicated in the disruption of collagen formation in a 
similar manner to ascorbate deficiency (19, 27). Hypoxia also accumulates 
lactate which stimulates collagen synthesis by collagen gene transcription and 
increasing the prolyl hydroxylase activity. However, trans-cutaneous oxygen 
tension is not uniform in the wound (19). The centre of the wound always has 
the lowest oxygen tension. In this particular area there is a decrease in the 
production of prolyl hydroxylase and therefore decreased collagen deposition. 
This explains why the centre of the wound is usually the last to heal (19, 21, 
22). In the opposite way, fibroblasts which are exposed to higher oxygen levels, 
respond by increasing collagen synthesis.  
 
 
 
 
 
 
 
Wounds that fail to heal 
Like other abnormal wounds, chronic wounds have decreased levels of 
factors such as proteinases, cytokines and growth factors that would normally 
promote wound healing (2). In addition, there may be higher levels of TNF-
alpha that decreases the activity of PDGF and EGF. 
TNF-alpha is also important in that it stimulates the matrix 
metalloproteinases, a group of proteolytic enzymes, into higher levels of activity 
and therefore increases the wound breakdown rates. This leads to an imbalance 
in the rate of wound healing, with degradation of the collagen based matrix 
being broken down faster than it can be formed. This pushes a wound towards 
chronicity (2, 23). 
The matrix metalloproteinases (33) further degrade the adhesive substrates 
and cytokine signaling molecules and reduce positive cell growth. The cellular 
degradation will also attract further inflammatory cells which pushes the wound 
towards further matrix degradation. Thus the entire process becomes one of 
negative cellular growth, and this process can be initiated at any time in the 
wound healing process. 
There are some other external factors that can affect wound healing and 
which predispose to chronicity (31). These are discussed below. 
 
Important factors affecting wound healing 
Infection 
This is probably the single most important reason for a wound to not heal 
(2). The presence of active infection as defined by a bacterial load of more than 
100,000 colonies per cc will prevent flap closure and delay primary healing 
(27). Some bacteria which release thermolysins and express other factors will 
further contribute to the process of matrix degradation. In the process they may 
release factors such as pro-MMP-1 which attract matrix metalloproteinases 
which further speed up the degradation process. 
 
Hypoxia 
Hypoxia (22, 27) in the form of ischemia due to atherosclerosis, cardiac 
failure or venous ulcers can cause a decrease in the local tissue oxygenation. 
The presence of molecular oxygen in a bound from is essential for the 
production of collagen, especially the post-translational cross-linking and triple 
helix formation. Once the trans-cutaneous oxygen tension falls below 40 mmHg 
in the wound, the quality of the collagen that is formed is poor. It tends to be 
brittle and easily degraded. Further, any process that causes local 
vasoconstriction such as smoking will further hypoxia. While it is true that 
hypoxia itself stimulates angiogenesis, a fall below 40 mmHg will not be of any 
benefit to the wound healing process. Anemia due to chronic disease can 
produce similar effects due to the reduced oxygen carrying capacity of the blood 
(27). 
 
Diabetes mellitus 
 
This chronic disease contributes to a large proportion of chronic wounds (1, 
3,22, 28). It affects wound healing at all stages. Tissue hypoxia, repetitive 
trauma, neuropathic effects and accelerated atherosclerosis all play a role in the 
poor wound healing. Peculiar to diabetes mellitus is the fact that increased 
glucose levels also cause additional glycosylation of the collagen matrix, 
causing it to be more brittle and susceptible to degradation as compared to 
normal collagen. 
 
Malnutrition 
 
Malnutrition (23) is well known to delay wound healing, especially when the 
metabolism of the body is in a catabolic phase and protein degradation is more 
than usual, as in burns, chronic diseases and post-operative periods. Vitamins A 
and K are also well known to be involved in wound healing, causing lysosomal 
membrane stability and preventing abnormal clotting through post-translational 
hydroxylative processes (27). 
Minerals such as zinc and iron and a few micro-nutrients such as selenium 
and manganese also play a role in promoting wound healing at the micro-
cellular level. These are important adjuncts and a normal diet will deliver 
adequate levels (27).  
 
 
 
 
 
 
 
 
 
 
 Advances in the treatment of chronic wounds 
 
Since the disease burden is so high and the economic ramifications so vast, 
there is a lot of interest in chronic wounds and in any treatment that could 
potentially decrease wound healing time. The most promising ones are 
mentioned here. 
Topical Applications 
Since  TGF-beta, PDGF and basic FGF are important cytokines in the 
process of wound healing, topical preparations of these were formulated in the 
mid-90’s and marketed aggressively, purporting the rapid closure of wounds or 
various kinds. However, this has not been borne out by any major randomized 
controlled trial (40). Until the exact growth factor required for the particular, 
individual wound is known, the use of growth factors seems to be mis-directed 
(36). 
Tissue engineering 
This allows genetic manipulation of any injured tissue, including 
myocardium and liver as well as epithelium. These are materials composed of 
cultured dermal fibroblasts mated to a polyglactide scaffolding that provides 
shape and support. Some of these also contain keratinocytes in the thought that 
they can grow into the host tissue. Once these are laid over the target area, they 
are replaced by the target tissues’ own skin cells. Some of these are FDA 
approved and are in current use. The evidence for this is limited to a few 
randomized controlled trials (32). 
Vacuum assisted closure devices 
These devices have shown great promise in the rapid healing of chronic 
wounds. They isolate the wound in a vacuum and continuous or intermittent 
suction up to 120 mmHg is applied over the wound. The effects of this are to 
keep the wound dry, prevent secondary bacterial infection and promote growth 
factors by active mechanical recruitment. These are commercially available as 
suction devices. The disadvantage is that they keep the patient confined to the 
bed and prevent early ambulation. The initial trials have shown great promise 
(4). 
 
Stem cell therapy 
This new branch of medicine has held great promise and is the current area 
of much research (8, 12, 16). Stem cells can be bone marrow derived or 
embryonic in nature. Their pluripotent nature should naturally allow them to 
differentiate into various cells types, especially in areas of cellular loss. 
However, unlocking the pathways of differentiation and culturing these cells 
towards active clinical use is still in an early stage. 
Bone marrow derived stem cells 
Stem cells can be embryonic or adult derived (8). They are known to 
incorporate themselves into tissue and to differentiate into required cell types. It 
is also well known that bone marrow in mammals contains progenitor or stem 
cells. Stem cells from bone marrow locally applied to chronic wounds have 
been shown to augment healing in animal studies (11, 24). A case report of 3 
patients with chronic wounds that did not heal with routine and advanced 
treatment had complete closure of the wounds after local application of bone 
marrow (5, 26). There is, however no evidence in a randomized controlled 
manner that shows conclusively that local application of bone marrow derived 
stem cells augments chronic wound healing.  
Stem cells derived from bone marrow can be hematopoietic or non-
hematopoietic in origin. They differentiate into various cell lines depending on 
the inherent genetic make-up, but can convert to other cells based on various 
stimuli (16). These may include growth factors, electrical stimuli, chemo-
attractants and various other cytokines, such as CD 34+. The exact stimulants 
required for differentiation into highly specialized cells such as keratinocytes 
still have to be accurately delineated (17). 
Case reports and series where autologous bone marrow derived stem cells 
have been injected or applied onto chronic wounds have shown promising 
results although it has taken up to 3 years in some cases for complete wound 
resolution (5, 26). Animal models have also shown promising results (11, 24). 
Cells engrafted onto the backs of wounded nude mice have been shown to 
incorporate into the healing tissue by use of GFP labeling (24). This has also 
been done in human volunteers successfully. 
There is also evidence to show that wounding is itself a stimulant for 
recruitment of these cells and that local cytokine release can serve as attractants 
for stem cells from the bone marrow as well as stem cells which are circulating 
peripherally (16, 17, 18). Therefore in theory the local stimulus should in fact 
cause these pluripotent cells to differentiate into the required fibroblasts, 
myofibroblasts and keratinocytes as well as dermal appendage precursors. 
The absence of this occurring conclusively has led to another postulate, 
namely that the stem cells do not completely engraft, but instead fuse with the 
cells that are already present and prolong their life-span while increasing their 
size and function. This has been borne out in work done since 2004 (13, 14). 
With this in mind, this thesis was devised to test in a randomized controlled 
manner whether the one time local application of bone marrow derived cells 
would improve the healing of chronic wounds over a fixed time period.  
 Methodology 
 
Patients who were seen in the surgical outpatient department of the Christian 
Medical College, Vellore and those referred for management of chronic wounds 
to the Department of General Surgery, formed the study population. The 
duration of the study was between July 2006 and July 2008.  This study 
received approval from the Institutional Review Board. 
Sample size calculation: 
Sample size equation for 2 independent groups was: 
n\group_2(Z_-Z__)\2 
where Z_ is the z-value for_ (Z value considered for p 0.05 is 1.96) 
where Z__ is standard deviation in mean response 
This came to a sample size of 63 cases and controls. However, given the 
rates of chronic wounds in the community (4.48\1000), it was calculated that a 
total number of 30 cases and 30 controls would suffice for a study power of 
80%, in conjunction with the Department of Biostatistics, CMC, Vellore. 
Statistical testing was done using the Student’s independent two-tailed t- test for 
unequal sample sizes with equal variance. All statistical analysis was done 
SPSS 16.0TM and all graphs were created using Microsoft Excel Office 2007TM , 
with the assistance of the Department of Biostatistics, CMC, Vellore.  
 
     
  Inclusion Criteria: 
• Male or female patients with chronic wounds that had not healed for 3 
months or more.  
• Wounds where primary closure could not be achieved.  
• Wounds which were unsuitable for skin grafting.   
  
Exclusion Criteria: 
• Wounds with active infection defined as copious pus discharge from 
the wound.  
• Wounds where distal pulses were not palpable  
• Wounds more than 15 cm in any one dimension.  
• Patients with Hansen’s disease.  
• Patients who were pregnant.  
• Patients who were on chemotherapy.  
• Patients who were diagnosed with hematological disease.  
 
After the patient was identified, he or she was consented for the study and 
recruited and given a unique identification number which was in series. 
Their hemoglobin levels and blood sugar levels were also recorded . 
The wound was measured and the longest and widest dimensions of the 
wound was measured to the nearest millimeter with a centimeter rule and 
documented. The measurements were from the edge of the wound.  
The wound was also photographed using a Nikon S5 camera in autofocus 
mode and with a flash. The distance from the wound was kept as close to 1 
meter as possible. The affected area was placed in anatomical position to allow 
for easy reproducibility in position for follow-up photographs (37). 
 
 
 Randomization 
Block randomization was carried out in blocks of 10 using opaque standard 
envelopes and were opened in the presence of the investigator by a neutral third 
party. 
 
Procedure  
Cases: 
Once the patient was randomized as a case, he or she had 10 cc of bone 
marrow aspirated from the posterior superior iliac spine under sedation and 
local anesthesia with strict aseptic precautions.  
The bone marrow aspirate was centrifuged at 3600 rpm for 20 minutes and 
the buffy coat pipetted off.  
Once the aspirate was prepared for injection, the wound bed was prepared by 
gently scraping it with the back of a forceps to encourage fresh surface bleeding 
(21).   
The buffy coat was then loaded into a 5 cc syringe and using a 26 G needle, 
2.5 cc was injected into the edges of the wound at four furthest points of the 
wounds and then at 4 intermediate equal positions between these equally.  
The remaining 2.5 cc of the stem cell concentrate was sprayed onto the 
wound.  
A saline dressing was done, adequate cotton pads applied over the wound 
and the patient was asked to follow up after 48 hours.  
At 48 hours, the wound was opened, measured, photographed and a saline 
dressing done. Regular dressings were continued as required.  
Controls: 
The procedure for the control patients was exactly the same as for the cases in 
terms of consenting, randomization and follow-up. However, instead of 
undergoing a bone marrow aspiration and local application of the centrifuged 
cells, they received local injection of autologous peripheral blood (6). Once the 
wound bed was prepared, then 5 cc of peripheral blood was drawn from the 
brachial vein of the left forearm and injected into the wound in exactly the 
manner outlined for bone marrow concentrates in the case group. 
 
Follow up 
The patients were followed up at 1week, 2 weeks, 4 weeks (25, 39), 6 weeks 
and at 3 months following the first application of centrifuged bone marrow 
aspirate.  
At each visit, the longest and widest dimensions (38) of the wound were 
measured from the edge and the wound photographed as for a surgical 
specimen.  
The endpoints of the study were considered achieved when the wounds 
achieved complete closure, or became suitable for conventional treatment 
options such as skin grafting, primary closure or at 3 months when the wounds 
were no longer followed up due to time constraints (26, 32).  
 
 
 
 
 
 
 
  
 
Data Analysis 
Baseline demographics 
Total number of patients recruited 
• Cases  25 
• Controls   24 
Total number of patients who completed follow-up 
• Cases   23 
• Controls  24 
Total number of patients lost to follow-up 
• Cases  2  
• Controls  0 
Average age of patients:  
• Cases  54 years and 3 months 
• Controls  58 years and 7 months 
 
 
Male to female ratio 
• Cases  17:8 
• Controls   15:9 
 
Adequate glycemic control:   All 
Number of patients with bilateral wounds 
• Cases  0 
• Controls   2 
Average wound age 
• Cases  14.28 months 
• Controls  10.21 months 
Maximum wound age 
• Cases  123 months 
• Controls  37 months 
 
 
Average initial wound size 
• Cases  65.32 cm2 
• Controls  48.83 cm2 
Average percentage reduction wound size by 3 months 
• Cases  36.40% 
• Controls  27.32% 
Number of wounds considered healed 
• Cases  10 
• Controls  7 
Percentage decrease in wound size at 2 weeks 
• Cases  17.0% 
• Controls  4.84% 
 Cases 
 
 
Graphical representation of changes in wound size over time in weeks 
following autologous bone marrow derived stem cell injection. (Fig 1) 
 
 Controls 
 
Graphical representation of changes in average wound size with time in weeks. 
(Fig 2) 
 
 
  
 
 
Comparison of average wound size over time between cases and controls.  
(Fig 3) 
 
 
 Typical case at first visit (Fig 4-1a). 
 
 
 
 
 
 Typical case at 6 weeks (Fig 4-1b). 
 
 
Typical control at 0 weeks ( Fig 4-2a) 
 
Typical control at 6 weeks (Fig 4-2b) 
New granulation tissue at injection sites (Fig 5) 
 
 Discussion: 
The data presented shows clearly that there is a decrease in the wound area size 
in the control group in the first two weeks after the intervention in the form of 
the autologous bone marrow injection to the wound. The decrease in average 
wound size at 2 weeks in the cases  is 17.4 % at 2 weeks as compared to 4.84 % 
in the control group. This is statistically significant (p< 0.05) 
The overall decrease in the wound area at the end of the 3 months is 36.4% in 
the cases while in the control group it is 27.32%. This is not statistically 
significant (p>0.05) 
The wounds in the cases which were considered to be healed were 10 in number 
(40%), while the controls had 7 wounds which were considered to be healed     
(29.2 %). This is statistically significant (p< 0.05). 
 
This study attempted to document whether the rate of wound healing in chronic 
wounds could be augmented by the local application of stem cells derived from 
autologous concentrated bone marrow aspirates. 
1. It is clear from the data collected and analyzed that the local application 
of bone marrow derived stem cells to chronic wounds does indeed 
increase the rate of wound healing as measured by the decrease in 
average wound size. This effect is maximal in the first two weeks after 
the injection and the effect appears to slowly decrease with time (Fig 1). 
2. In the control group there is also an initial small decrease in the wound 
area indicating better healing, but this could perhaps be attributed to bias 
in an unblended  study where the investigator takes greater interest in this 
wound knowing that it is part of a study. This is borne out by the rate of 
wound healing tapering off to a near plateau with time. Although the case 
group had a larger average wound size to begin with, there was no effect 
of this on the actual wound healing rate. 
3. The mechanisms of the effects of the autologous bone marrow injection 
to the chronic wounds, while being effective in the first two weeks, are 
not clear. If the stem cells were indeed dividing and differentiating (8, 9, 
12, 16) into the fibroblasts, keratinocytes and dermal appendages, the 
wound area curve should not have slowed. Furthermore the wounds 
should have epithelialized and closed of their own (26). In fact, none of 
the cases did this, and all the wounds that healed had undergone split 
thickness skin grafting once ready for it. This is borne out by work done 
on mice where the GFP labeled cells have been shown to have fused with 
the dermal cells in wounds on the backs of diabetic mice (11, 24). 
4. The other possible mechanisms that may be augmenting healing over this 
short period of two to four weeks following the intervention are the local 
cytokine factors (9,14,20)  such as TGF-alpha, FGF, CD 34+ and CD 14 
as well as a local increase in the oxygen tension of the wound (1,3,23). 
This could be the effect of the direct local application to the centre of the 
wound which is usually low in oxygen tension (1). This can be borne out 
by photographic evidence of new granulation tissue forming at the exact 
sites of injection in some of the wounds (Fig 5). 
5. There were six control wounds which closed spontaneously, although this 
can be explained by the fact that the largest area in the sub-group was 
8.32 cm2 and with normal wound contraction rates they would have 
closed spontaneously in the absence of any confounding factor. 
6. Since both case and control arms had adequate glycemic control (random 
blood sugar levels < 200 mg %) as evidenced by regular sugar monitoring 
either as inpatient or routine outpatient schedules, uncontrolled sugars 
cannot be said to be an impediment to healing. None of the patients had 
serum iron levels less than 7 mg % and anemia could therefore be ruled 
out as a confounding factor. 
7. There is evidence to show that in diabetic wounds the rate of healing at 4 
weeks is a robust indicator of whether the wound will become chronic or 
not (39). Figure 3 indicates that between 4 to 6 weeks is the time when 
the wound can be shown to have reached an obvious plateau in the 
healing rates, both in the cases and controls. 
8. Since the effects of the one-time intervention in the form of the 
autologous bone marrow injection are maximal in the first 2 weeks and 
then taper off, it may be judicious to consider a second application at the 
end of this period in order to further augment wound healing. This will 
need further large-scale trials and further work needs to be done to clarify 
the exact mechanism of its action. 
 
 
 
 
 
 
 
 
 
 
 
Final Conclusion 
1. The local application of autologous bone marrow derived stem cells in 
the treatment of chronic wounds does indeed augment healing as evidenced by 
decreasing wound area following the intervention.  
2. The effects are short-lived, the exact mechanisms unknown, but the 
positive effects on the wound are undeniable.  
3. It is therefore possible to recommend this technique as an option in 
attempting to bring healing to otherwise refractory chronic wounds according to 
the inclusion criteria mentioned.  
However, much work needs to be done to make this a more precise procedure. 
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Appendix 1: 
Patient information sheet. 
Your doctor has informed you that you have a wound which has not healed for three months or 
more or that your wound is unlikely to heal in the usual way by itself. This is known as a chronic 
wound.  He has also told you that there is a new method of treatment being evaluated which 
involves applying bone marrow from your body onto the wound in order to encourage the wound to 
heal more quickly. You are invited to take part in this study, but before you do so, it is important to 
understand why this research is being done and what would happen if you are involved. Please read 
the information below and do not hesitate to ask any questions. 
 
What is a chronic wound ? 
Any wound that does not heal within the usual duration of time is a chronic wound and for this 
study it is taken as any wound persisting beyond three months.  
What is bone marrow and why is it useful? 
Many bones in the body contain a substance called bone marrow which is the centre for blood 
cell manufacturing. It has cells called stem cells that can change into virtually any type of cell that 
the body needs. In this study we will be applying bone marrow onto and into the wound and 
assessing whether the wound heals more quickly than normal or not. 
What is the purpose of the study? 
In order to see whether applying the bone marrow actually helps the wound to heal faster or 
nor, we would like you to be part of a ‘randomized’ trial. Here you will be allocated to a group which 
either receives bone marrow to the wound or to a group where only blood is applied. Allocation is 
done by chance, so you have an equal chance of being in either group. Neither the doctor nor you 
know which group you will go to until after you decide to take part. 
Why are you chosen and do you have to take part? 
You have been chosen because you have a wound that has not healed for more than three 
months. You do not have to take part. If you decide to do take part, you will be asked to sign a 
consent form. If you do not take part, you will continue will your usual treatment and the care you 
receive will not be affected in any way. 
What will happen if I take part? 
Once you sign the consent form you will be allocated to receive bone marrow or only blood.  If 
you are allocated to receive bone marrow, your wound will be measured and photographed. Bone 
marrow will be taken from the back of your hip bone under local anaesthesia and injected and 
applied onto the wound. You will need to return for dressings as asked by your doctor for a total of 
five visits. 
If you are allocated to the group that does not receive bone marrow, blood will be drawn from 
one of your peripheral veins and injected and applied over the wound. You will need to return for 
dressings as asked by your doctor for a total of five visits. 
What are the side effects of taking part? 
These are expected to be very minimal and rare since the blood or the bone marrow to be used 
is from your own body. However, the wound could get infected as could the site from where the 
blood or bone marrow is taken. The risk of this is very low. 
Will my taking part be confidential? 
Yes. If you take part in the study, the doctors involved will look at your charts and other 
documents. This study is coordinated by the Department of General Surgery, Christian Medical 
College, Vellore. The information about you is stored on a computer and in confidential charts. No 
one other than the personnel in the study will have access to your records. 
What will happen to the results of the study? 
The data will be analysed. If there is a significant result, then it will change the way in which 
chronic wounds are being treated. 
Who has approved this study? 
This study has been cleared by the Department of General Surgery and the Ethics committee, 
Christian Medical College, Vellore. 
PATIENT CONSENT FORM. 
 
Patient Hospital Number:………………………………………………………….. 
 
Name of researcher:………………………………………………………………… 
 
1. I confirm that I, the undersigned, have read and understood the infromation sheet dated July 
2006 and have the chance to ask questions and clarify doubts. 
2. I understand that taking part in this study is voluntary and that I am free to withdraw at 
anytime, without giving any reason and that doing so will not affect my medical and legal 
rights. 
3. I understand that some of my medical notes will need to be looked at by responsible 
individuals from Christian Medical College, Vellore where the treatment is to be carried out. I 
give permission for these individuals to have access to my records. 
4. I agree to take part in the study mentioned in the information leaflet. 
 
 Name of Patient………………………………………Tel No……………………….. 
 
Address:……………………………………………………………………………………………………………………………………
…………………………………… 
 
Signature……………………………  Date:…………………………………… 
 
Name of Witness:……………………………………………………………………… 
 
Signature…………………………….  Date:……………………………………. 
 
Address of Witness:…………………………………………………………………… 
…………………………………………………………………………………………. 
………………………………………………………………………………………….. 
 
 
 
 
Appendix 2 
Data sheets: 
Cases 
 
Column1 Column2 Column3 Column4 Column5 Column6 Column7 Column8 Column9 Column10 Column11 Column12 
Serial No Hosp No Wound age Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 % reduction 
1 729350B 6 60.48 56 40.32 38.4 36.5 
2 978696C 4 8.6 8.4 7.98 7.4 6.8 20.93 
3 523187B 36 99.64 91.8 60.59 46.08 53.75 
4 542368C 8 52.46 49.2 48 45.82 42.12 19.71 
5 881761C 5 90.72 75.2 50.4 25.38 72.02 
6 789581C 7 120.4 113.6 99.56 74 57.12 49.6 58.8 
7 929636C 7 80 73.6 60.68 56.8 51.68 35.4 
8 094440D 4 14.08 12.9 12.6 10.64 9.99 8.88 42.05 
9 101135D 5 22.8 19.2 16.2 15.3 14.5 12.96 43.16 
10 `104485D 11 147.06 143.96 140.4 123.12 99.84 32.11 
11 113269D 8 40.32 36.6 31.8 30.16 26 44.75 
12 034716D 3 38.4 34.72 32.4 30 25.92 32.5 
13 131167D 4 99.84 93.84 6 
14 8 153.6 
15 595080C 6 55.4 52.3 50.2 46.2 38.72 32.7 40.97 
16 093790D 10 24.36 21.84 20.5 18.62 16.32 14.72 39.57 
17 727554C 123 146.88 138.72 135.34 122.88 116.56 110.4 24.84 
18 940820C 8 45.66 36.54 30.5 28.42 28.22 24.06 47.09 
19 157927D 18 36.54 34.76 30.2 28.88 26.13 25.12 31.25 
20 175146D 24 53.4 52.3 50.2 46.2 38.72 32.7 38.76 
21 919790C 7 86.28 73.6 60.48 58.8 51.68 40.1 
22 157311D 21 45.9 40.76 38.66 34.84 30.1 30 34.64 
23 418314B 5 21.22 18.26 13.29 13.01 12.44 10.76 49.29 
24 169080D 8 34.66 28.43 26.4 24.87 23.23 21.1 39.12 
25 850300C 11 54.24 48.54 46.21 44.2 40.06 39.76 26.7 
14.28 65.32 54.2 44.11 38.8 27.47 27.52 36.40% 
 
 
Controls 
 
Column1 Column2 Column3 Column4 Column5 Column6 Column7 Column8 Column9 Column10 Column11 Column12 
Serial No Hosp No Wound age Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 % reduction 
1 969731C 3 54.4 48.64 43.2 41.18 38.34 36.04 33.75 
2 960201C 2 22.26 20.8 19.38 17.28 15.64 14.85 33.28 
3 936829A 3.5 70.52 68 68.88 66.4 61.56 59.2 16.05 
4 822270C 5 4.6 3.96 3.2 1.5 67.39 
5 085786D 9 71.82 70.06 68.32 66 60.32 45.24 37.06 
6 131294D 1 8.32 8.32 3.12 67.18 
7 131282D 1 7.74 4.3 4.3 44.4 
8 097959D 7.5 118.8 112.64 99.2 92.72 88.8 86.14 27.49 
9 097959D 8 105.6 100.8 92.8 88 83.46 74.88 29.09 
10 957428C 9 9.6 9.28 8.96 8.37 7.54 6.72 30 
11 093790D 10 22.4 22 20.8 18.5 16.2 14.28 36.25 
12 579425C 12 72.36 65.52 62.22 58.58 52.64 27.25 
13 597425C 12 1.2 1.2 1.1 8.33 
14 165075D 16 23.65 22.21 20.1 20 18.65 17.24 27.1 
15 006204B 23 48.78 46.24 46.68 44.56 40.5 39.1 19.84 
16 529253C 12 44.24 42.21 43.67 42.27 40.58 40.26 8.97 
17 594004C 28 113.23 110.24 110.02 110.28 108.27 107.78 4.81 
18 029910D 2 3.6 3.2 2.87 2.08 42.22 
19 831366C 16 72.67 70.78 70.46 69.24 68.2 66.26 8.82 
20 831366C 18 76.88 74.24 70.2 68.46 68.26 67.29 12.4 
21 982080C 22 80.27 79.87 82.27 82.98 81.18 80.26 0.01 
22 153248D 3 32.27 32.02 31.35 28.46 28.33 27.1 16.02 
23 184299D 2 2.5 2.25 1.8 1.24 50.4 
24 126711C 37 104.28 100.48 98.96 97.26 95.29 96.54 7.42 
10.21 48.83 46.64 42.14 42.74 43.3 36.63 27.32% 
 
 
  
 
 
 
 
 
